Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06560606

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease

Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Juvenile Idiopathic Arthritis Arthritis Arthritis, Juvenile Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Alberta Children's Hospital - University of Calgary, Calgary, Alberta, Canada

Loading trial locations.

About this study

UCAN CAN-DU is a multicenter observational cohort study that will collect prospective data from children with arthritis. Biologic samples, clinical data and patient reported outcomes will be collected.

In addition, the study will also include a health economics component which will include a number of complementary approaches for quantifying and comparing benefits and risks that promote evidence-based, patient centered health care. This will address both the personal and societal economic burden of disease and include qualitative methods to inform the measurement of preferences, economic and simulation modelling to assess the value of biomarker testing. The socioeconomic impact of biomarker based treatment will be evaluated.

All clinical, biological and patient-derived data will be collected at an aggregation point housed and managed by High Performance Computing 4 Health (HPC4Health), a private hospital-only secure cloud-computing service within Compute Canada and physically located at SickKids/UHN. These databases and apps include biospecimen data and data collected through the eHealth platform. This will enable the study team to share and integrate data in near real-time into analytic models throughout the study course; hence providing a near real-time feedback from bench to bedside and vice versa.

The analysis of the cohorts will help define and confirm the biologic pathways predictive of disease course, treatment response and disease remission. This knowledge will then be used to develop a comprehensive clinical predictive tool to guide effective and safe treatment of childhood arthritis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cohort 1: - Biologic Basis of JIA

  • ≤18 years*
  • Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
  • Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis

Cohort 2 - Start Biologics

  • JIA diagnosis as per ILAR criteria (all subtypes)
  • ≤18 years*
  • Active arthritis
  • For sJIA, active disease not necessarily with arthritis.
  • Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance

Cohort 3 - Stop Biologics

  • JIA diagnosis as per ILAR criteria (all subtypes)
  • ≤18 years*
  • Inactive disease
  • Discontinuing/tapering biologics for inactive disease

Cohort 4: Extreme Phenotypes

  • Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
  • High suspicion of genetic contribution
  • Severely affected patients with difficult to control disease (ie failure of multiple biologics)

Exclusion criteria

Cohort 1 :

  • Arthritis explained by another diagnosis
  • Joint injections as previous treatment less than 4 weeks prior to enrollment

Cohort 2:

  • Arthritis explained by any other cause
  • Start on biologics as an indication for uveitis only

Cohort 3:

  • Tapering scheme > 12 months to complete biologics stop

Cohort 4:

  • Arthritis explained by another diagnosis

Treatment and study plan

Primary outcomes

  1. Prospectively collect essential clinical data elements from children with new onset JIA

    Time frame: Up to 24 months

  2. Evaluate clinical outcomes associated with the use of therapeutic agents in children with JIA

    Time frame: Up to 24 months

  3. Evaluate clinical outcomes associated with the de-prescribing of therapeutic agents in children with JIA

    Time frame: Up to 24 months

  4. Prospectively collect essential clinical data elements from children with extreme phenotypes of JIA.

    Time frame: Up to 12 months

  5. Prospectively collect essential biological data elements from children with new onset JIA

    Time frame: Up to 24 months

  6. Evaluate biological outcomes associated with the use of therapeutic agents in children with JIA

    Time frame: Up to 24 months

  7. Evaluate biological outcomes associated with the de-prescribing of therapeutic agents in children with JIA

    Time frame: Up to 24 months

  8. Prospectively collect essential biological data elements from children with extreme phenotypes of JIA

    Time frame: Up to 12 months

  9. Prospectively collect essential socioeconomic data elements from children with new onset JIA

    Time frame: Up to 12 months

  10. Evaluate the socioeconomic impact associated with the use of therapeutic agents in children with JIA

    Time frame: Up to 12 months

  11. Evaluate the socioeconomic impact associated with the de-prescribing of therapeutic agents in children with JIA

    Time frame: Up to 24 months

  12. Prospectively collect essential socioeconomic data elements from children with extreme phenotypes of JIA

    Time frame: Up to 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Alexander Mosoiu

CONTACT

[email protected]

416-813-7654 ext. 302495

Amy Xu

CONTACT

[email protected]

416-813-7654 ext. 302495

Sponsors and collaborators

Lead sponsor

The Hospital for Sick Children

Other

Collaborators

  • Alberta Children's Hospital
  • Canadian Institutes of Health Research (CIHR)
  • Genome Alberta
  • Genome Canada
  • Ontario Genomics
  • ReumaNederland
  • The Arthritis Society, Canada
  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Acronym: UCAN CAN-DU

Important dates

Study start
2018
Primary completion
2025
Study completion
2027
First posted
Aug 19, 2024
Registry last updated
Aug 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.